Timmermans, M., Sonke, G.S., van de Vijver, K.K., van der Aa, M.A. and Kruitwagen, R. (2018) No Improvement in Long-Term Survival for Epithelial Ovarian Cancer Patients: A Population-Based Study between 1989 and 2014 in the Netherlands. European Journal of Cancer, 88, 31-37.
https://doi.org/10.1016/j.ejca.2017.10.030

has been cited by the following article:

• TITLE: Research Progress of Nectin-4 as a Targeted Therapy for Ovarian Cancer

  AUTHORS: Xinmeng Wang, Jinzhi Lu, Cunjian Yi

  KEYWORDS: Ovarian Cancer, Nectin-4, Antibody Drug Conjugate (ADC), Targeted Therapy

  JOURNAL NAME: Yangtze Medicine, Vol.6 No.4, November 16, 2022

  ABSTRACT: Ovarian cancer is one of the most common gynecological malignancies. The 5-year survival rate of ovarian cancer is only 50%, which is considered to be the most lethal gynecologic malignant tumor.The high mortality of ovarian cancer patients can be attributed to chemotherapy resistance, extensive intraperitoneal metastasis and other factors.Tumor antigens are expressed on the surface of tumor cells and represent potential drug targets.One of the antigens is tumor associated nectin-4, which is a member of the immune globulin superfamily.This review highlights the role of nectin-4 as a therapeutic target for ovarian cancer, and discusses the relevant research data, which is an effective new direction in the treatment of ovarian cancer.Although there are still some challenges, targeted therapy is still a promising treatment for ovarian cancer.